CorMedix Licenses Two Antibiotic Assets for $70M Deal Ahead of Q2 Rezzayo Data
CorMedix entered a licensing agreement with Melinta for two late-stage antibiotic candidates under a $10 million upfront and $60 million milestone payment structure. The company anticipates Q2 Phase II rezzayo data, targeting clinical cure rates to support a pivotal Phase III launch.
1. Melinta Collaboration Details
CorMedix secured exclusive global rights to two late-stage antibiotic compounds from Melinta in exchange for a $10 million upfront payment, up to $60 million in development and regulatory milestones, and tiered low-single-digit royalties on future sales. The agreement covers indications in hospital-acquired and catheter-related bloodstream infections.
2. Pipeline Expansion and Strategic Shift
This partnership marks a strategic pivot from a single-product model to a diversified multi-product pharmaceutical company, adding an antibiotic portfolio alongside the lead agent rezzayo. Management aims to leverage existing commercial infrastructure once rezzayo is approved to support simultaneous launches of the new antibiotics.
3. Rezzayo Q2 Readout Timeline
Rezzayo’s Phase II trial is evaluating clinical cure at Day 21 in patients with catheter-associated bloodstream infections, with topline data expected in Q2 2026. Positive results could underpin the design of a pivotal Phase III program scheduled to initiate later this year.
4. Financial Implications and Valuation Impact
Analyst models forecast that a diversified pipeline could support peak sales exceeding $200 million by 2030, potentially prompting a multiple expansion. The upcoming Q2 data and integration of Melinta assets represent near-term catalysts for revenue projections and investor sentiment.